[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341519-105":59,"doc-detail-341519-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tertiary-lymphoid-structures-new-immunotherapy-biomarker","Tertiary lymphoid structures: new immunotherapy biomarker","","Immunotherapy has advanced cancer care but reliable biomarkers remain limited, motivating focused evaluation of tertiary lymphoid structures (TLSs). TLSs are organized aggregates resembling secondary lymphoid organs, arising postnatally in chronically inflamed tissues such as cancer. This review outlines TLS characteristics and formation-inducing factors, evaluates evidence linking TLS features to prognosis and response to immune checkpoint inhibitors across cancers, and highlights TLSs’ predictive potential for neoadjuvant immunotherapy efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tertiary-lymphoid-structures-new-immunotherapy-biomarker/341519/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tertiary-lymphoid-structures-new-immunotherapy-biomarker/341519.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are tertiary lymphoid structures (TLSs) and where do they form?","Question",{"text":112,"@type":113},"TLSs are organized immune cell aggregates resembling secondary lymphoid organs. Unlike secondary lymphoid organs, TLSs arise postnatally in nonlymphoid tissues under chronically inflamed conditions such as cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can TLSs act as biomarkers for immunotherapy response?",{"text":117,"@type":113},"TLS presence and specific TLS features correlate with patient prognosis and improved outcomes under immune checkpoint inhibitors. Evidence supports their predictive value independently of PD-L1 status, though effects can vary with TLS density, location, and maturation.",{"name":119,"@type":110,"acceptedAnswer":120},"What aspects of TLSs are examined in this review?",{"text":121,"@type":113},"The review describes TLS characteristics including cellular composition, density, location, maturation status, and gene signature, and summarizes how these features relate to immunotherapy response and cancer prognosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341519,1790562929,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Review  \nPUBLISHED 04 July 2024  \nDOI 10.3389/fimmu.2024.1394505  \nOPEN ACCESS  \nEDITED BY  \nNancy H. Ruddle,  \nYale University, United States  \nREVIEWED BY Ipsita Guha,  \nChildren ’s Hospital of Philadelphia, United States  \nDaniel Shu,  \nJohns Hopkins University, United States  \n*CORRESPONDENCE Xiaoyuan Chu  \n [chuxiaoyuan000@163.com](chuxiaoyuan000@163.com)[ ](chuxiaoyuan000@163.com)Cheng Chen  \n [chencheng1289@126.com](chencheng1289@126.com)[ ](chencheng1289@126.com)Meijuan Wu  \n[wmj2294@163.com](wmj2294@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 01 March 2024  \nACCEPTED 13 June 2024  \nPUBLISHED 04 July 2024  \nCITATION  \nYang F, Yang J, Wu M, Chen C and Chu X (2024) Tertiary lymphoid structures:  \nnew immunotherapy biomarker.  \nFront. Immunol. 15:1394505 .  \ndoi: 10.3389/fimmu.2024.1394505  \nCOPYRIGHT  \n© 2024 Yang, Yang, Wu, Chen and Chu. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTertiary lymphoid structures: new immunotherapy biomarker  \nFangyuan Yang1†, Jiahe Yang2†, Meijuan Wu 2*, Cheng Chen 2* and Xiaoyuan Chu 1,2*  \n1 Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China, 2 Department of Medical Oncology, Jinling Hospital, Afﬁliated Hospital of Medical School, Nanjing University, Nanjing, China  \nImmunotherapy shows substantial advancement in cancer and is becoming widely used in clinical practice. A variety of biomarkers have been proposed to predict the efﬁcacy of immunotherapy, but most of them have low predictive ability. Tertiary lymphoid structures (TLSs), the aggregation of multiple lymphocytes, have been found to exist in various tumor tissues. TLSs have been shown to correlate with patient prognosis and immunotherapy response. This review summarizes the characteristics of TLSs and the inducing factors of TLS formation, presents available evidence on the role of TLSs in predicting immunotherapy response in different cancers, and lastly emphasizes their predictive potential for neoadjuvant immunotherapy efﬁcacy.  \nKEYWORDS  \ntertiary lymphoid structures, cancer, immunotherapy, biomarker, cancer prognosis  \n1 Introduction  \nImmunotherapy has revolutionized cancer treatment and rejuvenated the ﬁeld of tumor immunology by enhancing patient ’ s immune response (1–3) . Cancer immunotherapy provides unprecedented rates of durable clinical beneﬁts for patients with different types of cancer, but the identiﬁcation of potential responders before immunotherapy remains to be a challenge (4) .  \nTertiary lymphoid structures (TLSs), sometimes referred to as ectopic lymphoid structures, are organized aggregates of immune cells resembling secondary lymphoid organs (SLO, e.g. lymph nodes and spleen) . Different from SLO, TLSs arise postnatally in nonlymphoid tissues under chronically inﬂamed environments, such as autoimmune diseases, allograft rejection, chronic inﬂammation and cancer (5) . Although the mature TLSs have similar structure to SLO, the cellular makeup and molecular pathways involved in the process of TLS formation vary due to different local tissue context and disease. The presence of TLSs typically contributed to superior prognosis of cancer patients (6) . Moreover, it has been reported that the presence of TLSs in tumor could predict an improved outcomes in cancer patients treated with immune checkpoint inhibitors (ICI) independently of PD-L1 status (7, 8) . For example, the survival rate of TLS positive patients has been proved to be higher than that of TLS negative group in non-small-cell lung cancer  \nFrontiers in Immunology 01 [fr","cbCaistdkpqz25MA","https://ap.wps.com/l/cbCaistdkpqz25MA","pdf",1575592,11,"English","# Introduction\n# Characterization of TLSs\n## TLS composition","[{\"question\":\"What are tertiary lymphoid structures (TLSs) and where do they form?\",\"answer\":\"TLSs are organized immune cell aggregates resembling secondary lymphoid organs. Unlike secondary lymphoid organs, TLSs arise postnatally in nonlymphoid tissues under chronically inflamed conditions such as cancer.\"},{\"question\":\"How can TLSs act as biomarkers for immunotherapy response?\",\"answer\":\"TLS presence and specific TLS features correlate with patient prognosis and improved outcomes under immune checkpoint inhibitors. Evidence supports their predictive value independently of PD-L1 status, though effects can vary with TLS density, location, and maturation.\"},{\"question\":\"What aspects of TLSs are examined in this review?\",\"answer\":\"The review describes TLS characteristics including cellular composition, density, location, maturation status, and gene signature, and summarizes how these features relate to immunotherapy response and cancer prognosis.\"}]","Tertiary lymphoid structures: new immunotherapy biomarker | PDF",1790042349,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73a6ea4f52bd637ef95312d5bf814c98.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c5df9120cf19f569d72db6ba91f4670.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/192857a549da21993198d3d958faa58b.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d2b7aa16852f421040b491cebb5aa5b.webp",980,1385]